Stock Market News
Tuesday tips round-up: Hiscox, Reckitt Benckiser, GlaxoSmithKline
29-07-2014 07:56
Add To Google +1 | Tweet |
Insurance outfit Hiscox is one of the most respected names in its sector and for good reason. For the first half of the year the outfit achieved a combined ratio of 82%. That marks a deterioration on the 74.7% seen in the comparable period of the year before but is nevertheless a good result. The company also improved the returns its makes on investing the money from premiums which it takes in, to 2%, while the dividend was raised by 7% to 7.5p, although it is too soon to say whether it will repeat the trick of repurchasing share capital to the tune of 11%, as it has over the past couple of years.
More importantly perhaps, the firm is concentrating on smaller-ticket business instead of going after lower margin higher-ticket work. Even so, the shares are currently changing hands at a 63% premium to net asset value, which looks a bit high for the sector. "The company is well run and profitable, but there is growing competition in the insurance market and the valuation on the shares is high", so 'hold' says The Times' Tempus.
Sometimes it's better to follow different paths in life. When? Well, you know when the moment comes. So it is too in the corporate world. Yesterday both Reckitt Benckiser and GlaxoSmithKline (GSK) effectively set out plans to separate their pharmaceutical and consumer healthcare divisions. Indeed, given the former's reliance on R&D and the latter's need for marketing and cultivating relationships with retailers it may be best to let each side focus on what it does best.
Nonetheless, that is not always the case. That is because pharma products can sometimes be turned into consumer ones. Thus, Bayer recently bought Merck's consumer unit and for the moment at least GSK is merging its own consumer business with that of Novartis. Absent those operational crossovers however a separation is often best, writes the Financial Times' Lex column.
Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.
AB
More importantly perhaps, the firm is concentrating on smaller-ticket business instead of going after lower margin higher-ticket work. Even so, the shares are currently changing hands at a 63% premium to net asset value, which looks a bit high for the sector. "The company is well run and profitable, but there is growing competition in the insurance market and the valuation on the shares is high", so 'hold' says The Times' Tempus.
Sometimes it's better to follow different paths in life. When? Well, you know when the moment comes. So it is too in the corporate world. Yesterday both Reckitt Benckiser and GlaxoSmithKline (GSK) effectively set out plans to separate their pharmaceutical and consumer healthcare divisions. Indeed, given the former's reliance on R&D and the latter's need for marketing and cultivating relationships with retailers it may be best to let each side focus on what it does best.
Nonetheless, that is not always the case. That is because pharma products can sometimes be turned into consumer ones. Thus, Bayer recently bought Merck's consumer unit and for the moment at least GSK is merging its own consumer business with that of Novartis. Absent those operational crossovers however a separation is often best, writes the Financial Times' Lex column.
Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.
AB
Related share prices |
---|
GlaxoSmithKline (GSK) share price |
Reckitt Benckiser Group (RB.) share price |
Hiscox Limited (DI) (HSX) share price |
Stock News is provided by Digital Look Corporate Solutions from Sharecast news. Please read the terms and conditions of useage of this data. Republication or redistribution of content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd.
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- RBS share price
- Diageo share price
- Standard Life Share Price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- Morrisons Share Price
- Aviva Share Price
- LGO Share price
- Tullow Oil Share Price
- SXX Share Price
- Easyjet Share Price
- Next Share Price
- Thomas Cook Share Price
- SSE Share Price
- IAG Share Price
- Bat share price
- Monitise Share Price
- Kingfisher share price
- Dragon Oil share price
- UKOG share price
- SOLG share price